Kennedy Jr., who was tapped to lead the Department of Health and Human Services for the Trump administration, recently ...

Zepbound contains the same active ingredient, tirzepatide, as Mounjaro, which is also made by Lilly and is FDA-approved to treat Type 2 diabetes. Some doctors also prescribe Mounjaro "off-label" for ...

Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...

How weight loss drugs actually work, and how big-name prescriptions differ from each other. What investors need to know about ...

Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, ...

The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents.

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks Jim Cramer recently discussed. In a recent appearance on CNBC’s Squawk on ...

(CNN) — Eli Lilly, the maker of blockbuster weight loss ... aim to build on the weight-loss success of Zepbound, including a pill in development called orforglipron that’s expected to have ...

Eli Lilly plans to invest $27 billion in four new pharmaceutical manufacturing facilities in the U.S., expanding its domestic production of medications across multiple therapeutic areas.

Eli Lilly LLY.N plans to spend at least $27 billion to build four new manufacturing plants in the U.S., the drugmaker said at a Washington press conference on Wednesday, as it grapples with the ...

Eli Lilly said Wednesday it will invest $27 billion to build four new manufacturing plants in the United States as the pharmaceutical giant grapples with the threat of drug import duties from the ...